CN103379901B - 含有氯化甲基息奥宁的配方 - Google Patents

含有氯化甲基息奥宁的配方 Download PDF

Info

Publication number
CN103379901B
CN103379901B CN201180057700.9A CN201180057700A CN103379901B CN 103379901 B CN103379901 B CN 103379901B CN 201180057700 A CN201180057700 A CN 201180057700A CN 103379901 B CN103379901 B CN 103379901B
Authority
CN
China
Prior art keywords
mtc
composition
tablet
tablets
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180057700.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103379901A (zh
Inventor
卡拉尔·阿哈默德·卡恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CN103379901A publication Critical patent/CN103379901A/zh
Application granted granted Critical
Publication of CN103379901B publication Critical patent/CN103379901B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180057700.9A 2010-11-30 2011-11-30 含有氯化甲基息奥宁的配方 Active CN103379901B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41816410P 2010-11-30 2010-11-30
US61/418,164 2010-11-30
PCT/GB2011/001662 WO2012072977A2 (en) 2010-11-30 2011-11-30 Compound formulations

Publications (2)

Publication Number Publication Date
CN103379901A CN103379901A (zh) 2013-10-30
CN103379901B true CN103379901B (zh) 2018-04-03

Family

ID=45418703

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180057700.9A Active CN103379901B (zh) 2010-11-30 2011-11-30 含有氯化甲基息奥宁的配方

Country Status (10)

Country Link
US (1) US9192611B2 (OSRAM)
EP (1) EP2645994B1 (OSRAM)
JP (1) JP6093707B2 (OSRAM)
CN (1) CN103379901B (OSRAM)
AU (1) AU2011334679B2 (OSRAM)
CA (1) CA2818068C (OSRAM)
ES (1) ES2655492T3 (OSRAM)
MY (1) MY163074A (OSRAM)
SG (2) SG190406A1 (OSRAM)
WO (1) WO2012072977A2 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014153444A (ja) * 2013-02-06 2014-08-25 Konica Minolta Inc 位相差フィルム、偏光板及び液晶表示装置
EP3487505B1 (en) 2016-07-25 2023-05-03 WisTa Laboratories Ltd. Administration and dosage of diaminophenothiazines
FR3104438B1 (fr) * 2019-12-12 2021-11-19 Univ Bordeaux Formulation pour le bleu de methylene et procede
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
AU2023346900A1 (en) 2022-09-21 2025-04-10 TauRx Therapeutics Management Ltd Novel formulations and vehicles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880373A (en) 1988-04-28 1989-11-14 The Upjohn Company Tablet press
JPH0840942A (ja) * 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 薬物放出制御製剤
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
SI2322517T1 (sl) 2004-09-23 2019-06-28 Wista Laboratories Ltd. Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC)
RS51271B (sr) * 2004-10-19 2010-12-31 Krka Tovarna Zdravil D.D. Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
AU2006283121A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
DK1808165T3 (da) * 2006-01-05 2009-08-03 Teva Pharma Törre formuleringer af aripiprazol
MY143757A (en) 2006-03-29 2011-07-15 Wista Lab Ltd 3,7-diamond-10h-phenothiazine salts and their use
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
SI2954932T1 (sl) 2007-10-03 2019-01-31 Wista Laboratories Ltd. Terapevtska uporaba diaminofenotiazinov
WO2009060191A2 (en) 2007-11-05 2009-05-14 Wista Laboratories Ltd. Systems for clinical trials
PT2480540T (pt) * 2009-09-24 2018-02-16 Wista Lab Ltd Pentahidrato de cloreto de metiltionínio e respetivas preparação e utilização farmacêutica

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Phosphasal;www.drugs.com;《www.drugs.com》;20100801;第1页第2段 *

Also Published As

Publication number Publication date
AU2011334679A1 (en) 2013-07-18
AU2011334679B2 (en) 2016-12-15
MY163074A (en) 2017-08-15
JP2013544272A (ja) 2013-12-12
US9192611B2 (en) 2015-11-24
EP2645994A2 (en) 2013-10-09
SG10201602111VA (en) 2016-04-28
EP2645994B1 (en) 2017-11-01
WO2012072977A2 (en) 2012-06-07
JP6093707B2 (ja) 2017-03-08
US20130243858A1 (en) 2013-09-19
CA2818068C (en) 2019-06-11
SG190406A1 (en) 2013-06-28
WO2012072977A8 (en) 2012-09-20
WO2012072977A3 (en) 2012-08-16
CN103379901A (zh) 2013-10-30
CA2818068A1 (en) 2012-06-07
ES2655492T3 (es) 2018-02-20

Similar Documents

Publication Publication Date Title
JPWO2003082279A1 (ja) 単一の結晶形を含有する固形製剤
US20100137358A1 (en) Solifenacin compositions
TW202446397A (zh) 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
CN103379901B (zh) 含有氯化甲基息奥宁的配方
US12357630B2 (en) Ceritinib formulation
CN103372014B (zh) 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法
JP2008536922A (ja) オランザピンの医薬用経口崩壊錠
WO2020111089A1 (ja) 医薬組成物
CN106511291A (zh) 一种盐酸阿考替胺缓释片剂及其制备方法
CA2912738A1 (en) Stable crystal i-form agomelatine tablet and preparation method thereof
CN112057427B (zh) 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
JP7506475B2 (ja) フェブキソスタット製剤
HK1184386B (en) Formulations comprising methylthioninium chloride
HK1184386A (en) Formulations comprising methylthioninium chloride
TW202404585A (zh) 含有匹密特匹(Pimitespib)之醫藥組合物
CN113143873A (zh) 一种多塞平口崩片制剂及其制备方法
HK1229715B (en) Ceritinib formulation
HK1229715A1 (en) Ceritinib formulation
BR112019020269B1 (pt) Dispersão sólida, composição farmacêutica, seus usos e seus métodos de preparação
BR112019020269A2 (pt) formulação farmacêutica

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant